Drug Type CAR-NKT |
Synonyms BP 2202 (BrightPath), BP2202 (BrightPath) |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | Japan | 01 Jul 2025 | |
Hematologic Neoplasms | Preclinical | Japan | - |